Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No Prescription? No Problem: FDA Draft Rule Gives Green Light To OTC Hearing Aids

Executive Summary

The US FDA’s proposed reg, released on 19 October, aims to get more hearing aids into the ears of those who need them by allowing the devices to be purchased over the counter.

You may also be interested in...

US House Sends Slew Of Health Bills To Senate

The US House of Representatives passed more than a dozen bipartisan bills that seek to increase funding for various public health initiatives, including biomedical research.

Audiologist Group Has Concerns About US FDA's Proposal For OTC Sales Of Hearing Aids

With FDA proposal to allow OTC hearing aid sales mostly met with approval, American Speech-Language-Hearing Association says consumers risk further hearing loss by not consulting with professionals.

Hear! Hear! Industry Responds To FDA Proposal On OTC Hearing Aids

The FDA’s recent proposal to allow hearing aids to be sold over the counter without a prescription has mostly been met with approval. Many Americans, however, are unaware of the plan.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts